注册 | 登录 | 充值

首页-> 学术资讯 -> 文献解读

【热门文献】来自婴儿口中的诺如病毒

文献解读

2022-08-04      

852 0


染色体不稳定性(CIN)驱动癌细胞进化、转移和治疗耐药性,并与不良预后相关1。CIN导致微核,破裂后将DNA释放到细胞质中,从而触发cGAS和STING介导的炎症信号的激活。这两种蛋白被认为是肿瘤抑制因子,因为它们促进细胞凋亡和免疫监视。然而,cGAS和STING在癌症中很少失活,虽然它们与转移有关,但尚不清楚为什么在原发肿瘤中没有出现功能丧失突变。


cGAS STING信号的失活选择性地损害了显示CIN的三阴性乳腺癌细胞的生存。CIN触发IL-6 stat3介导的信号通路,依赖于cGAS STING通路和非典型NF-κB通路。通过tocilizumab阻断IL-6信号,一种临床使用的药物,靶向IL-6受体(IL-6R),有选择性地损害培养的三阴性乳腺癌细胞的生长,显示CIN。此外,与不显示CIN的肿瘤相比,染色体不稳定肿瘤的生长明显延迟。


研究证明cGAS STING信号通路的致瘤特性,并解释cGAS STING通路在原发肿瘤中很少失活的原因。重新使用托珠单抗可能是治疗CIN过表达IL-6R的癌症的一种策略。


Abstract

Chromosomal instability (CIN) drives cancer cell evolution, metastasis and therapy resistance, and is associated with poor prognosis1. CIN leads to micronuclei that release DNA into the cytoplasm after rupture, which triggers activation of inflammatory signalling mediated by cGAS and STING2,3. These two proteins are considered to be tumour suppressors as they promote apoptosis and immunosurveillance. However, cGAS and STING are rarely inactivated in cancer4, and, although they have been implicated in metastasis5, it is not known why loss-of-function mutations do not arise in primary tumours4. Here we show that inactivation of cGAS–STING signalling selectively impairs the survival of triple-negative breast cancer cells that display CIN. CIN triggers IL-6–STAT3-mediated signalling, which depends on the cGAS–STING pathway and the non-canonical NF-κB pathway. Blockade of IL-6 signalling by tocilizumab, a clinically used drug that targets the IL-6 receptor (IL-6R), selectively impairs the growth of cultured triple-negative breast cancer cells that exhibit CIN. Moreover, outgrowth of chromosomally instable tumours is significantly delayed compared with tumours that do not display CIN. Notably, this targetable vulnerability is conserved across cancer types that express high levels of IL-6 and/or IL-6R in vitro and in vivo. Together, our work demonstrates pro-tumorigenic traits of cGAS–STING signalling and explains why the cGAS–STING pathway is rarely inactivated in primary tumours. Repurposing tocilizumab could be a strategy to treat cancers with CIN that overexpress IL-6R.


原文链接

https://www.nature.com/articles/s41586-022-04847-2



科研资讯(站内):

百度浏览   来源 : 医微客   


版权声明:本网站所有注明来源“医微客”的文字、图片和音视频资料,版权均属于医微客所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源:”医微客”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,转载仅作观点分享,版权归原作者所有。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。 本站拥有对此声明的最终解释权。

科研搜索(百度):医学科研





发表评论

注册或登后即可发表评论

登录注册

全部评论(0)

没有更多评论了哦~

科研资讯 更多>>
  • Nature子刊:涂毅恒团队揭示慢性..
  • Nature重磅:只需一针,让免疫系..
  • 刚刚!院外送检!卫健委点名!..
  • 脂肪肝到肝癌,只需要4步!每天..
  • 推荐阅读 更多>>
  • 【热门文献】雄性的求食行为是由..
  • 【热门文献】睡眠时乳腺癌的转移..
  • 【热门文献】2型心肌梗死患者氧..
  • 【热门文献】卒中发生后血管内取..
    • 相关阅读
    • 热门专题
    • 推荐期刊
    • 学院课程
    • 医药卫生
      期刊级别:国家级期刊
      发行周期:暂无数据
      出版地区:其他
      影响因子:暂无数据
    • 中华肿瘤
      期刊级别:北大核心期刊
      发行周期:月刊
      出版地区:北京
      影响因子:1.90
    • 中华医学
      期刊级别:CSCD核心期刊
      发行周期:周刊
      出版地区:北京
      影响因子:0.94